In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering:

• How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases

He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines.

Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.